Markers of response to CDK4 & 6 inhibition from neoMONARCH: A phase II neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive, HER2 negative breast cancer

被引：1
|
作者：
Hurvitz, S.
Martin, M.
Wijayawardana, S.
Brahmachary, M.
Ebert, Pj
Young, S.
Jansen, V.
Slamon, D.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P3-10-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-10-08
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Final results of NeoMONARCH: A phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC)
    Martin, Miguel
    Hurvitz, Sara A.
    Chan, David
    Fernandez-Abad, Maria
    Petru, Edgar
    Rostorfer, Regan
    Guarneri, Valentina
    Huang, Chiun-Sheng
    Press, Michael F.
    Costigan, Timothy M.
    Caldwell, Charles W.
    Wijayawardana, Sameera
    Turner, P. Kellie
    Barriga, Susana
    Slamon, Dennis J.
    CANCER RESEARCH, 2018, 78 (04)
  • [2] Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
    Migliaccio, Ilenia
    Leo, Angela
    Galardi, Francesca
    Guarducci, Cristina
    Fusco, Giulio Maria
    Benelli, Matteo
    Di Leo, Angelo
    Biganzoli, Laura
    Malorni, Luca
    CANCERS, 2021, 13 (11)
  • [3] Treatment with abemaciclib modulates the immune response in gene expression analysis of the neoMONARCH neoadjuvant study of abemaciclib in postmenopausal women with HR+, HER2 negative breast cancer
    Hurvitz, S.
    Martin, M.
    Press, M.
    Wijayawardana, S.
    Brahmachary, M.
    Ebert, P. J.
    Young, S.
    Jansen, V.
    Slamon, D.
    CANCER RESEARCH, 2019, 79 (04)
  • [4] Interim results from neoMONARCH: A neoadjuvant phase II study of abemaciclib in postmenopausal women with HR +/HER2-breast cancer (BC)
    Hurvitz, S.
    Abad, M. F.
    Rostorfer, R.
    Chan, D.
    Egle, D.
    Huang, C-S.
    Barriga, S.
    Costigan, T. M.
    Caldwell, C. W.
    Schilder, J. M.
    Press, M. F.
    Slamon, D.
    Martin, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] A phase II study of neoadjuvant abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (neoMONARCH)
    Hurvitz, Sara A.
    Schilder, Jeanne Marie
    Frenzel, Martin
    Martin, Miguel
    CANCER RESEARCH, 2016, 76
  • [6] The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
    Bao, Kelvin K. H.
    Sutanto, Leone
    Tse, Shirley S. W.
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)
    Laguna, J. C.
    Braso-Maristany, F.
    Pascual, T.
    Rodriguez Hernandez, A.
    Chic, N.
    Schettini, F.
    Sanfeliu Torres, E.
    Gonzalez-Farre, B.
    Martinez, D.
    Galvan, P.
    Diez-Guardia, V.
    Adamo, B.
    Vidal, M.
    Guillen Sacoto, M. C.
    Moreno, R.
    Prat, A.
    Munoz, M.
    Martinez-Saez, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S69 - S70
  • [8] A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive (HR+) HER2 negative (HER2-) breast cancer
    Li, Allen
    Naik, Arpana
    Johnson, Nathalie
    Goodyear, Shaun
    Johnson, Brett
    Park, Byung
    Corless, Christopher
    Gray, Joe
    Mills, Gordon
    Mitri, Zahi
    CANCER RESEARCH, 2021, 81 (04)
  • [9] Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
    Boyle, Frances
    Beith, Jane
    Burslem, Katie
    de Boer, Richard
    Hui, Rina
    Lim, Elgene
    McCarthy, Nicole
    Redfern, Andrew
    Woodward, Natasha
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 3 - 11
  • [10] CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects
    Wekking, Demi
    Leoni, Vera Piera
    Lambertini, Matteo
    Dessi, Mariele
    Pretta, Andrea
    Cadoni, Andrea
    Atzori, Luigi
    Scartozzi, Mario
    Solinas, Cinzia
    CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 75 : 57 - 64
12345